<DOC>
	<DOCNO>NCT00578409</DOCNO>
	<brief_summary>We seek improve predictive accuracy nomogram predict survival patient castrate mets disease addition pathological data , result automate machine vision base image analysis H &amp; E stain tumor tissue develop Aureon Biosciences , molecular biomarker study ( 25 marker ) determine immunohistochemistry tissue microarrays prepare paraffin-embedded tumor .</brief_summary>
	<brief_title>Identification Predictive Factors Survival Patients With Recurrent Prostate Cancer From Clinical Features , Tissue Image Features Molecular Biomarker Data</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients first retrospective study ( Stage 1 ) must part 409 patient strong MSKCC cohort progressive metastatic prostate cancer use generation original nomogram . For detail please see original publication Smaletz et al . Patients involved second retrospective study ( Stage 2 ) must part 223 patient rise PSA surgery radiation therapy treat conjugate vaccine trial MSKCC.. For detail exclude patient clinical metastasis castrate disease study , please see original publication Smaletz et al.4 â€¢ ( MSKCC add reference publication available rise PSA patient )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>progressive castrate metastatic prostate cancer</keyword>
</DOC>